Wednesday March 13, 8:30 am Eastern Time - SOURCE: MicroLight Corporation

MICROLIGHT CORPORATION ANNOUNCES MEDICAL ADVISORY DIRECTOR FOR “COLD LASER” THERAPY OF CARPAL TUNNEL SYNDROME  

Missouri City, Texas  (Business Wire), March 13, 2002 - Microlight Corporation announced today the addition of Dr. Michael I. Weintraub to its Medical Advisory Board.  Dr. Weintraub is a pioneer in the field of “cold laser” technology.  He has published several articles and written books on the breakthrough technology of “photo-bio stimulation”.  He is also a guest speaker around the world on the subject of “cold laser” therapy in soft tissue injury.  Dr. Weintraub is currently Clinical Professor of Neurology and Medicine at New York Medical College in Valhalla, N.Y., and also Adjunct Clinical Professor of Neurology at Mt. Sinai School of Medicine, New York City.

“ F.D.A. clearance for the use of the “MicroLight 830 Cold Laser” therapy in the treatment of Carpal Tunnel Syndrome represents a major breakthrough in photobio stimulation technology in medicine. There are many other soft tissue indications for use of “cold laser” therapy. This is just the beginning of a new era of laser technology in medicine”, stated Dr. Michael I. Weintraub.

“We are very excited about having the “Pioneer” of Laser Technology in Neurology join our Medical Advisory Board.  His clinical and research experience will be invaluable to the technology and the company”, stated Mike Barbour, MicroLight’s President.

Microlight Corporation is the first company to get F.D.A. clearance to market Low level laser therapy for the non surgical treatment of Carpal Tunnel Syndrome. Carpal Tunnel Syndrome is the number one repetitive stress injury problem in the work force, costing the health care industry over $10 billion a year.

Back